Patents by Inventor Stephane Depil

Stephane Depil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
    Patent number: 9492423
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: November 15, 2016
    Assignee: PHARMACYCLICS LLC
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian, Ioana Kloos, Stephane Depil
  • FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF
    Publication number: 20140341989
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: September 13, 2011
    Publication date: November 20, 2014
    Applicants: PHARMACYCLICS, INC.
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian, Ioana Kloos, Stephane Depil
  • Administration regime for N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2- ylcarbonylamino]ethoxy}benzamide
    Patent number: 8883199
    Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterized in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: November 11, 2014
    Assignees: Les Laboratoires Servier, Pharmacyclics, Inc.
    Inventors: Ioana Kloos, Renata Robert, Anne Jacquet-Bescond, Stephane Depil, Marylore Chenel, Sylvain Fouliard, Sriram Balasubramanian
  • T CD4+ Epitopes of Type I and II Latency Antigens of the Epstein-Barr Virus, Which Can Be Recognized by the majority of individuals in the caucasian populations and applications thereof
    Publication number: 20090130134
    Abstract: The invention relates to immunogenic peptides from EBV type I and II latency antigens, comprising at least one T CD4+ epitope which can be recognized by the majority of individuals in the Caucasian population. The invention also relates to the diagnostic and therapeutic applications of same.
    Type: Application
    Filed: February 2, 2006
    Publication date: May 21, 2009
    Inventors: Veronique Pancre, Claude Auriault, Stephane Depil, Bernard Maillere, Olivier Morales, Gaetan Munier